NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Sell
34
XPH Quote, Financials, Valuation and Earnings
Last price:
$43.25
Seasonality move
:
0.25%
Day range:
$43.07 - $43.97
52-week range:
$38.88 - $48.76
Dividend yield:
1.61%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
58.3K
Avg. volume:
61.3K
1-year change:
9.21%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
XPH
SPDR S&P Pharmaceuticals ETF
|
-- | -- | -- | -- | -- |
|
BBH
VanEck Biotech ETF
|
-- | -- | -- | -- | -- |
|
CNCR
Range Cancer Therapeutics ETF
|
-- | -- | -- | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- |
|
PILL
Direxion Daily Pharmaceutical & Medical Bl 3X Shs
|
-- | -- | -- | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
XPH
SPDR S&P Pharmaceuticals ETF
|
$43.42 | -- | -- | -- | $0.19 | 1.61% | -- |
|
BBH
VanEck Biotech ETF
|
$158.56 | -- | -- | -- | $0.71 | 0% | -- |
|
CNCR
Range Cancer Therapeutics ETF
|
$12.09 | -- | -- | -- | $0.00 | 0% | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
$67.22 | -- | -- | -- | $0.01 | 0.05% | -- |
|
PILL
Direxion Daily Pharmaceutical & Medical Bl 3X Shs
|
$7.31 | -- | -- | -- | $0.03 | 1.59% | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
$82.67 | -- | -- | -- | $0.20 | 0.93% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
XPH
SPDR S&P Pharmaceuticals ETF
|
-- | 1.021 | -- | -- |
|
BBH
VanEck Biotech ETF
|
-- | 1.127 | -- | -- |
|
CNCR
Range Cancer Therapeutics ETF
|
-- | 2.118 | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | 1.301 | -- | -- |
|
PILL
Direxion Daily Pharmaceutical & Medical Bl 3X Shs
|
-- | 2.336 | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | 0.832 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
XPH
SPDR S&P Pharmaceuticals ETF
|
-- | -- | -- | -- | -- | -- |
|
BBH
VanEck Biotech ETF
|
-- | -- | -- | -- | -- | -- |
|
CNCR
Range Cancer Therapeutics ETF
|
-- | -- | -- | -- | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- | -- |
|
PILL
Direxion Daily Pharmaceutical & Medical Bl 3X Shs
|
-- | -- | -- | -- | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | -- | -- | -- | -- | -- |
SPDR S&P Pharmaceuticals ETF vs. Competitors
-
Which has Higher Returns XPH or BBH?
VanEck Biotech ETF has a net margin of -- compared to SPDR S&P Pharmaceuticals ETF's net margin of --. SPDR S&P Pharmaceuticals ETF's return on equity of -- beat VanEck Biotech ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XPHSPDR S&P Pharmaceuticals ETF-- -- -- BBHVanEck Biotech ETF-- -- -- -
What do Analysts Say About XPH or BBH?
SPDR S&P Pharmaceuticals ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand VanEck Biotech ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Pharmaceuticals ETF has higher upside potential than VanEck Biotech ETF, analysts believe SPDR S&P Pharmaceuticals ETF is more attractive than VanEck Biotech ETF.
Company Buy Ratings Hold Ratings Sell Ratings XPHSPDR S&P Pharmaceuticals ETF0 0 0 BBHVanEck Biotech ETF0 0 0 -
Is XPH or BBH More Risky?
SPDR S&P Pharmaceuticals ETF has a beta of 0.759, which suggesting that the stock is 24.059% less volatile than S&P 500. In comparison VanEck Biotech ETF has a beta of 0.727, suggesting its less volatile than the S&P 500 by 27.303%.
-
Which is a Better Dividend Stock XPH or BBH?
SPDR S&P Pharmaceuticals ETF has a quarterly dividend of $0.19 per share corresponding to a yield of 1.61%. VanEck Biotech ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.71 per share. SPDR S&P Pharmaceuticals ETF pays -- of its earnings as a dividend. VanEck Biotech ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XPH or BBH?
SPDR S&P Pharmaceuticals ETF quarterly revenues are --, which are smaller than VanEck Biotech ETF quarterly revenues of --. SPDR S&P Pharmaceuticals ETF's net income of -- is lower than VanEck Biotech ETF's net income of --. Notably, SPDR S&P Pharmaceuticals ETF's price-to-earnings ratio is -- while VanEck Biotech ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Pharmaceuticals ETF is -- versus -- for VanEck Biotech ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XPHSPDR S&P Pharmaceuticals ETF-- -- -- -- BBHVanEck Biotech ETF-- -- -- --
-
Which has Higher Returns XPH or CNCR?
Range Cancer Therapeutics ETF has a net margin of -- compared to SPDR S&P Pharmaceuticals ETF's net margin of --. SPDR S&P Pharmaceuticals ETF's return on equity of -- beat Range Cancer Therapeutics ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XPHSPDR S&P Pharmaceuticals ETF-- -- -- CNCRRange Cancer Therapeutics ETF-- -- -- -
What do Analysts Say About XPH or CNCR?
SPDR S&P Pharmaceuticals ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Range Cancer Therapeutics ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Pharmaceuticals ETF has higher upside potential than Range Cancer Therapeutics ETF, analysts believe SPDR S&P Pharmaceuticals ETF is more attractive than Range Cancer Therapeutics ETF.
Company Buy Ratings Hold Ratings Sell Ratings XPHSPDR S&P Pharmaceuticals ETF0 0 0 CNCRRange Cancer Therapeutics ETF0 0 0 -
Is XPH or CNCR More Risky?
SPDR S&P Pharmaceuticals ETF has a beta of 0.759, which suggesting that the stock is 24.059% less volatile than S&P 500. In comparison Range Cancer Therapeutics ETF has a beta of 0.903, suggesting its less volatile than the S&P 500 by 9.71%.
-
Which is a Better Dividend Stock XPH or CNCR?
SPDR S&P Pharmaceuticals ETF has a quarterly dividend of $0.19 per share corresponding to a yield of 1.61%. Range Cancer Therapeutics ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SPDR S&P Pharmaceuticals ETF pays -- of its earnings as a dividend. Range Cancer Therapeutics ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XPH or CNCR?
SPDR S&P Pharmaceuticals ETF quarterly revenues are --, which are smaller than Range Cancer Therapeutics ETF quarterly revenues of --. SPDR S&P Pharmaceuticals ETF's net income of -- is lower than Range Cancer Therapeutics ETF's net income of --. Notably, SPDR S&P Pharmaceuticals ETF's price-to-earnings ratio is -- while Range Cancer Therapeutics ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Pharmaceuticals ETF is -- versus -- for Range Cancer Therapeutics ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XPHSPDR S&P Pharmaceuticals ETF-- -- -- -- CNCRRange Cancer Therapeutics ETF-- -- -- --
-
Which has Higher Returns XPH or PBE?
Invesco Biotechnology & Genome ETF has a net margin of -- compared to SPDR S&P Pharmaceuticals ETF's net margin of --. SPDR S&P Pharmaceuticals ETF's return on equity of -- beat Invesco Biotechnology & Genome ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XPHSPDR S&P Pharmaceuticals ETF-- -- -- PBEInvesco Biotechnology & Genome ETF-- -- -- -
What do Analysts Say About XPH or PBE?
SPDR S&P Pharmaceuticals ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Biotechnology & Genome ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Pharmaceuticals ETF has higher upside potential than Invesco Biotechnology & Genome ETF, analysts believe SPDR S&P Pharmaceuticals ETF is more attractive than Invesco Biotechnology & Genome ETF.
Company Buy Ratings Hold Ratings Sell Ratings XPHSPDR S&P Pharmaceuticals ETF0 0 0 PBEInvesco Biotechnology & Genome ETF0 0 0 -
Is XPH or PBE More Risky?
SPDR S&P Pharmaceuticals ETF has a beta of 0.759, which suggesting that the stock is 24.059% less volatile than S&P 500. In comparison Invesco Biotechnology & Genome ETF has a beta of 0.819, suggesting its less volatile than the S&P 500 by 18.07%.
-
Which is a Better Dividend Stock XPH or PBE?
SPDR S&P Pharmaceuticals ETF has a quarterly dividend of $0.19 per share corresponding to a yield of 1.61%. Invesco Biotechnology & Genome ETF offers a yield of 0.05% to investors and pays a quarterly dividend of $0.01 per share. SPDR S&P Pharmaceuticals ETF pays -- of its earnings as a dividend. Invesco Biotechnology & Genome ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XPH or PBE?
SPDR S&P Pharmaceuticals ETF quarterly revenues are --, which are smaller than Invesco Biotechnology & Genome ETF quarterly revenues of --. SPDR S&P Pharmaceuticals ETF's net income of -- is lower than Invesco Biotechnology & Genome ETF's net income of --. Notably, SPDR S&P Pharmaceuticals ETF's price-to-earnings ratio is -- while Invesco Biotechnology & Genome ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Pharmaceuticals ETF is -- versus -- for Invesco Biotechnology & Genome ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XPHSPDR S&P Pharmaceuticals ETF-- -- -- -- PBEInvesco Biotechnology & Genome ETF-- -- -- --
-
Which has Higher Returns XPH or PILL?
Direxion Daily Pharmaceutical & Medical Bl 3X Shs has a net margin of -- compared to SPDR S&P Pharmaceuticals ETF's net margin of --. SPDR S&P Pharmaceuticals ETF's return on equity of -- beat Direxion Daily Pharmaceutical & Medical Bl 3X Shs's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XPHSPDR S&P Pharmaceuticals ETF-- -- -- PILLDirexion Daily Pharmaceutical & Medical Bl 3X Shs-- -- -- -
What do Analysts Say About XPH or PILL?
SPDR S&P Pharmaceuticals ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Direxion Daily Pharmaceutical & Medical Bl 3X Shs has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Pharmaceuticals ETF has higher upside potential than Direxion Daily Pharmaceutical & Medical Bl 3X Shs, analysts believe SPDR S&P Pharmaceuticals ETF is more attractive than Direxion Daily Pharmaceutical & Medical Bl 3X Shs.
Company Buy Ratings Hold Ratings Sell Ratings XPHSPDR S&P Pharmaceuticals ETF0 0 0 PILLDirexion Daily Pharmaceutical & Medical Bl 3X Shs0 0 0 -
Is XPH or PILL More Risky?
SPDR S&P Pharmaceuticals ETF has a beta of 0.759, which suggesting that the stock is 24.059% less volatile than S&P 500. In comparison Direxion Daily Pharmaceutical & Medical Bl 3X Shs has a beta of 2.234, suggesting its more volatile than the S&P 500 by 123.445%.
-
Which is a Better Dividend Stock XPH or PILL?
SPDR S&P Pharmaceuticals ETF has a quarterly dividend of $0.19 per share corresponding to a yield of 1.61%. Direxion Daily Pharmaceutical & Medical Bl 3X Shs offers a yield of 1.59% to investors and pays a quarterly dividend of $0.03 per share. SPDR S&P Pharmaceuticals ETF pays -- of its earnings as a dividend. Direxion Daily Pharmaceutical & Medical Bl 3X Shs pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XPH or PILL?
SPDR S&P Pharmaceuticals ETF quarterly revenues are --, which are smaller than Direxion Daily Pharmaceutical & Medical Bl 3X Shs quarterly revenues of --. SPDR S&P Pharmaceuticals ETF's net income of -- is lower than Direxion Daily Pharmaceutical & Medical Bl 3X Shs's net income of --. Notably, SPDR S&P Pharmaceuticals ETF's price-to-earnings ratio is -- while Direxion Daily Pharmaceutical & Medical Bl 3X Shs's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Pharmaceuticals ETF is -- versus -- for Direxion Daily Pharmaceutical & Medical Bl 3X Shs. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XPHSPDR S&P Pharmaceuticals ETF-- -- -- -- PILLDirexion Daily Pharmaceutical & Medical Bl 3X Shs-- -- -- --
-
Which has Higher Returns XPH or PJP?
Invesco Pharmaceuticals ETF has a net margin of -- compared to SPDR S&P Pharmaceuticals ETF's net margin of --. SPDR S&P Pharmaceuticals ETF's return on equity of -- beat Invesco Pharmaceuticals ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XPHSPDR S&P Pharmaceuticals ETF-- -- -- PJPInvesco Pharmaceuticals ETF-- -- -- -
What do Analysts Say About XPH or PJP?
SPDR S&P Pharmaceuticals ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Pharmaceuticals ETF has higher upside potential than Invesco Pharmaceuticals ETF, analysts believe SPDR S&P Pharmaceuticals ETF is more attractive than Invesco Pharmaceuticals ETF.
Company Buy Ratings Hold Ratings Sell Ratings XPHSPDR S&P Pharmaceuticals ETF0 0 0 PJPInvesco Pharmaceuticals ETF0 0 0 -
Is XPH or PJP More Risky?
SPDR S&P Pharmaceuticals ETF has a beta of 0.759, which suggesting that the stock is 24.059% less volatile than S&P 500. In comparison Invesco Pharmaceuticals ETF has a beta of 0.580, suggesting its less volatile than the S&P 500 by 42.037%.
-
Which is a Better Dividend Stock XPH or PJP?
SPDR S&P Pharmaceuticals ETF has a quarterly dividend of $0.19 per share corresponding to a yield of 1.61%. Invesco Pharmaceuticals ETF offers a yield of 0.93% to investors and pays a quarterly dividend of $0.20 per share. SPDR S&P Pharmaceuticals ETF pays -- of its earnings as a dividend. Invesco Pharmaceuticals ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XPH or PJP?
SPDR S&P Pharmaceuticals ETF quarterly revenues are --, which are smaller than Invesco Pharmaceuticals ETF quarterly revenues of --. SPDR S&P Pharmaceuticals ETF's net income of -- is lower than Invesco Pharmaceuticals ETF's net income of --. Notably, SPDR S&P Pharmaceuticals ETF's price-to-earnings ratio is -- while Invesco Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Pharmaceuticals ETF is -- versus -- for Invesco Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XPHSPDR S&P Pharmaceuticals ETF-- -- -- -- PJPInvesco Pharmaceuticals ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is up 4.46% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 10.25% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 4.77% over the past day.
